<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; venture</title>
	<atom:link href="http://www.tapanray.in/tag/venture/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Takes ‘Two to Tango’: Encashing Opportunities with Biologic drugs in India</title>
		<link>http://www.tapanray.in/takes-two-to-tango-encashing-opportunities-with-biologic-drugs-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=takes-two-to-tango-encashing-opportunities-with-biologic-drugs-in-india</link>
		<comments>http://www.tapanray.in/takes-two-to-tango-encashing-opportunities-with-biologic-drugs-in-india/#comments</comments>
		<pubDate>Mon, 11 Feb 2013 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Avesthagen]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[capital]]></category>
		<category><![CDATA[DBT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[large]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[molecule]]></category>
		<category><![CDATA[Orchid]]></category>
		<category><![CDATA[patent-cliff]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[PwC]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reliance]]></category>
		<category><![CDATA[SBIRI]]></category>
		<category><![CDATA[Shanta]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[tango]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[venture]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1408</guid>
		<description><![CDATA[Despite current ‘Patent Cliff’ ongoing research on biologics is now at the forefront of the Global Pharmaceutical Industry.  The bottom-line impact of a successful new biologic molecule to treat intractable ailments like, cancer, blood disorders, Parkinson&#8217;s, Myasthenia Gravis, Multiple Sclerosis, &#8230; <a href="http://www.tapanray.in/takes-two-to-tango-encashing-opportunities-with-biologic-drugs-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/takes-two-to-tango-encashing-opportunities-with-biologic-drugs-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
